Wikipedia -WSS

Wikipedia

author：focus 2025-09-29 22:50:01 - browse：87

Two hands hold a box of four Wegovy pens — first opinion coverage from STAT — Cydni Elledge/The New York Times

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong.

Yet beneath the hype lies a real fear. Unless we reverse the rising tide of metabolic syndrome, Medicare will be crushed, with tens of millions of Americans having shorter, harder lives. The new drugs offer the first real chance to deploy at scale treatments to halt a seemingly unstoppable trend.

That will be costly. But so is the status quo. Medicare spending on people with advanced metabolic disease is sobering. Beneficiaries with two or more of the costliest conditions — diabetes, heart failure, or chronic kidney disease — comprise just 10% of beneficiaries, according to the NIH’s Renal Data System 2022 Annual Data Report. Yet they account for 25% of total costs. Those with all three conditions are 2% of beneficiaries but almost 7% of costs. And remember, the current cohort of Medicare beneficiaries turned 65 when obesity and diabetes rates were lower, meaning unless we do something dramatic, and fast, these percentages will balloon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Readout LOUD podcast: mifepristone case, GLP

WSS

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

FDA's naming rule on biosimilars has undermined competition

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

Merck drug for rare lung condition set for approval in U.S.

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

focus

Wikipedia

focus

Jerome Adams on the need for new antivirals for Covid

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

Hepatitis C has a cure — but many Americans still lack access to it

Study says nonprofit hospitals fall short in charity care spending

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Roche subsidiary Foundation Medicine opens new headquarters

Apple is now the first public company to be valued at $3 trillion

Military medical care influenced by rank and race, new study finds

Medical records are filled with copy

Patient advocates debate FDA's accelerated approval process

knowledge

Decaf coffee targeted by food safety group under obscure FDA rule

Vertex Pharmaceuticals may move headquarters in Boston

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

explore

explore

leisure time

leisure time